相关实验视频
Updated: Jul 5, 2025

03:22
Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
Published on: November 10, 2023
721
胸腔整形以缓解急性心力衰竭中的多流:多中心,开放标签,随机对照TAP-IT试验的研究协议
Signe Glargaard1, Jakob Hartvig Thomsen2, Brian Bridal Løgstrup3,4
1Department of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark signe.glargaard@regionh.dk.
BMJ open
|January 20, 2024
概括
这项试验旨在调查早期胸腔切除是否能改善急性心力衰竭患者的结局. 它比较了导管排水加药与单独服用药物,以减少住院治疗.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 干预医学是干预的医学.
背景情况:
- 在50%的住院病例中,多溢液会使急性心力衰竭复杂化.
- 目前的治疗方法,如利尿剂和胸腔切除,缺乏随机试验证据,证明了与心力衰竭相关的多叶流液.
- 胸腔整形以缓解心脏腹溢血干预试验 (TAP-IT) 解决了这一证据缺口.
研究的目的:
- 为了确定早期胸腔切除是否能改善急性心力衰竭患者的临床结果.
- 为了比较前置猪尾导管胸腔注射加标准药理疗与单独药理疗的策略.
- 评估对随机化后90天内活着且未入院的天数的影响.
主要方法:
- 一个务实,多中心,开放标签,随机对照试验 (NCT05017753).
- 将招募126名成年患者,他们的左心室喷射分数≤45%和由于心力衰竭而引起的显著的肺部溢液.
- 参与者按1:1随机分配到早期胸腔切除加标准护理或单独标准护理,按部位和抗凝剂使用分层.
主要成果:
- 主要终点:存活几天,随机化后90天内出院.
- 二级终点包括90天死亡率,并发症率,再入院和生活质量.
- 将对治疗意图人口进行分析.
结论:
- 该TAP-IT试验将提供关键证据,证明早期胸腔缩在治疗急性心力衰竭与多流液时的有效性.
- 研究结果将为这种常见并发症的临床指导方针和治疗策略提供信息.
- 该研究旨在通过减少住院时间和死亡率来改善患者的治疗结果.
相关概念视频
Endoscopic Studies II: Thoracocentesis
264
Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
264
Pneumothorax-II
153
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
153
Pleural Effusion II: Symptoms and Management
179
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
179
Pneumothorax-I
211
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
211
Flail Chest-II
174
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
174
Acute Respiratory Failure-V
141
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
141

